dtc tests using snps (23andMe)
90
Structured Review
23andMe
dtc tests using snps
Dtc Tests Using Snps, supplied by 23andMe, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dtc+testing/dtc+testing/pm40570721-57-7-35
Average 90 stars, based on 1 article reviews
Dtc Tests Using Snps, supplied by 23andMe, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dtc+testing/dtc+testing/pm40570721-57-7-35
Average 90 stars, based on 1 article reviews
dtc tests using snps - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
Sequencing:Article Title: Genetic counseling following direct-to consumer genetic testing: Consumer perspectives. Article Snippet: 1Department of Human Genetics, University of Michigan, Ann Arbor, MI, USA 2Swedish Medical Center, Seattle, WA, USA 3Department of Health Behavior and Health Education, School of Public Health, University of Michigan, Ann Arbor, MI, USA 4Center for Bioethics and Social Sciences in Medicine, University of Michigan, Ann Arbor, MI, USA 5Department of Learning Health Sciences, University of Michigan Medical School, Ann Arbor, MI, USA 6Dana Farber Cancer Institute, Boston, MA, USA 7Division of Genetics, Department of Medicine, Brigham and Women’s Hospital, Boston, MA, USA 8Harvard Medical School, Boston, MA, USA 9Division of Genetic Medicine, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA Article Title: Parkinson's disease variant detection and disclosure: PD GENEration, a North American study. Article Snippet: Lola Cook, Jennifer Verbrugge, Tae-Hwi Schwantes-An, Jeanine Schulze, Tatiana Foroud, Anne Hall, Karen S. Marder, Ignacio F. Mata, Niccolò E. Mencacci, Martha A. Nance, Michael A. Schwarzschild, Tanya Simuni, Susan Bressman, Anne-Marie Wills, Hubert H. Fernandez, Irene Litvan, Kelly E. Lyons, Holly A. Shill, Carlos Singer, Thomas F. Tropea, Nora Vanegas Arroyave, Janfreisy Carbonell, Rossy Cruz Vicioso, Linn Katus, Joseph F. Quinn, Priscila D. Hodges, Yan Meng, Samuel P. Strom, Cornelis Blauwendraat, Katja Lohmann, Cynthia Casaceli, Shilpa C. Rao, Kamalini Ghosh Galvelis, Anna Naito, James C. Beck and Roy N. Alcalay on behalf of the Parkinson’s Foundation and Parkinson Study Group PD GENEration investigators Article Title: Direct-to-Consumer Genetic Testing: Value and Risk. Article Snippet: Although the explosive growth of direct-to-consumer (DTC) genetic testing has moderated, a substantial number of patients are choosing to undergo genetic testing outside the purview of their regular healthcare providers.. Further, many industry leaders have been expanding reports to cover many more genes, as well as partnering with employers and others to expand access.. This review addresses continuing concerns about DTC genetic testing quality, psychosocial impact, integration withmedical practice, effects on the healthcare system, and privacy, as well as emerging concerns about thirdparty interpretation services and non-health-related uses such as investigative genetic genealogy. Article Title: Retrospective Cohort Study on the Limitations of Direct-to-Consumer Genetic Screening in Hereditary Breast and Ovarian Cancer Article Snippet: However, on the basis of their review in 2018, Article Title: Direct-to-Consumer Genetic Testing for Cardiovascular Disease: A Scientific Statement From the American Heart Association Article Snippet: Despite insufficient evidence to support direct-to-consumer genetic testing in routine clinical care, cardiovascular clinicians increasingly face questions about its utility and interpretation because individuals can purchase these tests directly from laboratories.. A burgeoning marketplace offers an expanding array of testing options.. In many cases, direct-to-consumer genetic testing advertises information that could inform one’s risk of heritable disease, including insight into having a genetic predisposition to cardiovascular disease or data about gene-drug interactions that could affect response to cardiovascular medications. Article Title: Long-read Sequencing for Germline Pharmacogenomic Testing Article Snippet: KEY POINTS Clinical pharmacogenomic testing is increasingly available due to the growing interest in implementing pharmacogenomic-guided medication management.. Targeted genotyping has historically been the most common platform for pharmacogenomic testing; however, the major limitation with this approach is the inability to directly phase identified variants and alleles.. Many clinically actionable pharmacogenomic genes have well-characterized haplotypes that use the star (*) allele nomenclature system. Activity Assay:Article Title: Genetic counseling following direct-to consumer genetic testing: Consumer perspectives. Article Snippet: 1Department of Human Genetics, University of Michigan, Ann Arbor, MI, USA 2Swedish Medical Center, Seattle, WA, USA 3Department of Health Behavior and Health Education, School of Public Health, University of Michigan, Ann Arbor, MI, USA 4Center for Bioethics and Social Sciences in Medicine, University of Michigan, Ann Arbor, MI, USA 5Department of Learning Health Sciences, University of Michigan Medical School, Ann Arbor, MI, USA 6Dana Farber Cancer Institute, Boston, MA, USA 7Division of Genetics, Department of Medicine, Brigham and Women’s Hospital, Boston, MA, USA 8Harvard Medical School, Boston, MA, USA 9Division of Genetic Medicine, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA Article Title: Parkinson's disease variant detection and disclosure: PD GENEration, a North American study. Article Snippet: Lola Cook, Jennifer Verbrugge, Tae-Hwi Schwantes-An, Jeanine Schulze, Tatiana Foroud, Anne Hall, Karen S. Marder, Ignacio F. Mata, Niccolò E. Mencacci, Martha A. Nance, Michael A. Schwarzschild, Tanya Simuni, Susan Bressman, Anne-Marie Wills, Hubert H. Fernandez, Irene Litvan, Kelly E. Lyons, Holly A. Shill, Carlos Singer, Thomas F. Tropea, Nora Vanegas Arroyave, Janfreisy Carbonell, Rossy Cruz Vicioso, Linn Katus, Joseph F. Quinn, Priscila D. Hodges, Yan Meng, Samuel P. Strom, Cornelis Blauwendraat, Katja Lohmann, Cynthia Casaceli, Shilpa C. Rao, Kamalini Ghosh Galvelis, Anna Naito, James C. Beck and Roy N. Alcalay on behalf of the Parkinson’s Foundation and Parkinson Study Group PD GENEration investigators Article Title: Direct-to-Consumer Genetic Testing: Value and Risk. Article Snippet: Although the explosive growth of direct-to-consumer (DTC) genetic testing has moderated, a substantial number of patients are choosing to undergo genetic testing outside the purview of their regular healthcare providers.. Further, many industry leaders have been expanding reports to cover many more genes, as well as partnering with employers and others to expand access.. This review addresses continuing concerns about DTC genetic testing quality, psychosocial impact, integration withmedical practice, effects on the healthcare system, and privacy, as well as emerging concerns about thirdparty interpretation services and non-health-related uses such as investigative genetic genealogy. Article Title: Retrospective Cohort Study on the Limitations of Direct-to-Consumer Genetic Screening in Hereditary Breast and Ovarian Cancer Article Snippet: However, on the basis of their review in 2018, Article Title: Direct-to-Consumer Genetic Testing for Cardiovascular Disease: A Scientific Statement From the American Heart Association Article Snippet: Despite insufficient evidence to support direct-to-consumer genetic testing in routine clinical care, cardiovascular clinicians increasingly face questions about its utility and interpretation because individuals can purchase these tests directly from laboratories.. A burgeoning marketplace offers an expanding array of testing options.. In many cases, direct-to-consumer genetic testing advertises information that could inform one’s risk of heritable disease, including insight into having a genetic predisposition to cardiovascular disease or data about gene-drug interactions that could affect response to cardiovascular medications. Article Title: Long-read Sequencing for Germline Pharmacogenomic Testing Article Snippet: KEY POINTS Clinical pharmacogenomic testing is increasingly available due to the growing interest in implementing pharmacogenomic-guided medication management.. Targeted genotyping has historically been the most common platform for pharmacogenomic testing; however, the major limitation with this approach is the inability to directly phase identified variants and alleles.. Many clinically actionable pharmacogenomic genes have well-characterized haplotypes that use the star (*) allele nomenclature system. |